1. Home
  2. EARN vs SKYE Comparison

EARN vs SKYE Comparison

Compare EARN & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EARN
  • SKYE
  • Stock Information
  • Founded
  • EARN 2012
  • SKYE 2012
  • Country
  • EARN United States
  • SKYE United States
  • Employees
  • EARN N/A
  • SKYE N/A
  • Industry
  • EARN Real Estate Investment Trusts
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • EARN Real Estate
  • SKYE Health Care
  • Exchange
  • EARN Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • EARN 177.0M
  • SKYE 172.9M
  • IPO Year
  • EARN 2013
  • SKYE N/A
  • Fundamental
  • Price
  • EARN $6.92
  • SKYE $6.99
  • Analyst Decision
  • EARN Hold
  • SKYE Strong Buy
  • Analyst Count
  • EARN 2
  • SKYE 5
  • Target Price
  • EARN $6.00
  • SKYE $18.40
  • AVG Volume (30 Days)
  • EARN 374.0K
  • SKYE 157.3K
  • Earning Date
  • EARN 08-12-2024
  • SKYE 08-09-2024
  • Dividend Yield
  • EARN 13.82%
  • SKYE N/A
  • EPS Growth
  • EARN 102.38
  • SKYE N/A
  • EPS
  • EARN 0.23
  • SKYE N/A
  • Revenue
  • EARN $18,419,000.00
  • SKYE N/A
  • Revenue This Year
  • EARN N/A
  • SKYE N/A
  • Revenue Next Year
  • EARN $51.24
  • SKYE N/A
  • P/E Ratio
  • EARN $29.84
  • SKYE N/A
  • Revenue Growth
  • EARN N/A
  • SKYE N/A
  • 52 Week Low
  • EARN $5.09
  • SKYE $1.44
  • 52 Week High
  • EARN $7.26
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • EARN 50.09
  • SKYE 61.35
  • Support Level
  • EARN $6.76
  • SKYE $5.71
  • Resistance Level
  • EARN $7.04
  • SKYE $6.69
  • Average True Range (ATR)
  • EARN 0.10
  • SKYE 0.71
  • MACD
  • EARN -0.01
  • SKYE 0.15
  • Stochastic Oscillator
  • EARN 48.44
  • SKYE 81.71

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: